Digestive system

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

Retrieved on: 
Monday, May 24, 2021
Science, Biotechnology, Research, Pharmaceutical, Managed care, General Health, Health, Clinical trials, Clinical medicine, Medical specialties, Medicine, Abdominal pain, Irritable bowel syndrome, Digestive system, Bloating, Defecation, Constipation, Linaclotide, Ironwood Pharmaceuticals, LINACLOTIDE, IRONWOOD PHARMACEUTICALS

More than a third of surveyed IBS-C patients indicated their symptoms had worsened during the COVID-19 pandemic.

Key Points: 
  • More than a third of surveyed IBS-C patients indicated their symptoms had worsened during the COVID-19 pandemic.
  • Also, nearly half (46%) of surveyed IBS-C patients reported that they did not seek care from a healthcare provider in the past year for their symptoms.
  • Most common bothersome symptoms in the past seven days included abdominal discomfort, abdominal pain, straining, abdominal bloating and incomplete bowel movements.
  • Ironwood Pharmaceuticals also presented six other posters at the meeting, four of which were posters of distinction.

Gnubiotics gains allowance of patent of microbiome markers for prediction, identification and treatment of pet obesity from the European Patent Office

Retrieved on: 
Monday, May 24, 2021
Branches of biology, Medical specialties, Microbiomes, Microbiology, Bacteriology, Digestive system, Environmental microbiology, Firmicutes, Gut microbiota, Obesity, Microbiome, Gastrointestinal tract

This is a key patent filing covering the microbiome-based prediction, identification and treatment of feline obesity.\nAccording to the Association for Pet Obesity Prevention, an estimated 56% of dogs and 60% of cats were overweight or obese in 2018.

Key Points: 
  • This is a key patent filing covering the microbiome-based prediction, identification and treatment of feline obesity.\nAccording to the Association for Pet Obesity Prevention, an estimated 56% of dogs and 60% of cats were overweight or obese in 2018.
  • We believe that early detection and predictive microbome based modalities could provide more effective methods for management of chronic diseases in our pets."
  • commented Dr. Yemi Adesokan, Chief Scientific Officer and Co-Founder ofGnubiotics.\nBacteria that reside in human and animal guts are called collectively the gut microbiome.
  • These bacteria play a vital role in the digestion of essential nutrients as well as defense against undesirable gut microbes.

Ferring and Rebiotix Present Positive Interim Phase 3 Results From Open-Label Study of Investigational Microbiota-Based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)

Retrieved on: 
Saturday, May 22, 2021
Science, Biotechnology, Research, Pharmaceutical, Managed care, Health, Infectious diseases, Clinical trials, Medical specialties, Clinical medicine, Gastroenterology, Gastrointestinal tract disorders, Autoimmune diseases, Abdominal pain, Inflammatory bowel disease, Digestive system, Irritable bowel syndrome, Clostridioides difficile, Gastrointestinal tract

The study also enrolled patients diagnosed with co-morbid conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Key Points: 
  • The study also enrolled patients diagnosed with co-morbid conditions such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
  • The patients enrolled closely reflect the recurrent C. difficile infection patients who healthcare providers treat every day.
  • The results were presented at Digestive Disease Week\xc2\xae (DDW) 2021, taking place virtually this year from May 21-23.\nThis press release features multimedia.
  • 2012;55(S2):S154\xe2\x80\x9361.\nLangdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.

RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021

Retrieved on: 
Friday, May 21, 2021
Medical specialties, Clinical medicine, Branches of biology, Digestive system, Gastroenterology, Morphinans, Opioid antagonists, Diarrhea, Helicobacter pylori, Naloxegol, Helicobacter, Opioid

We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.

Key Points: 
  • We then used the new classifications to assess the efficacy of rifamycin, reconfirming highly statistically significant efficacy across both newly reclassified moderate and severe patient groups.
  • "\n"Outcomes-focused clinical tools to assess the prognosis in TD have been lacking, and the development of this new Travelers\' Diarrhea severity classification tool provides prognostic information that may help guide clinical practice," said June Almenoff, M.D., Ph.D., FACP, RedHill\'s Chief Medical Officer.
  • RedHill promotes the gastrointestinal drugs, Movantik for opioid-induced constipation in adults[vii], Taliciafor the treatment of Helicobacter pylori (H. pylori) infection in adults[viii], and Aemcolo for the treatment of travelers\' diarrhea in adults[ix].
  • All forward-looking statements included in this press release are made only as of the date of this press release.

New Study Suggests Visbiome Vet May Support Gastrointestinal Health in Dogs Undergoing Chemotherapy Treatment

Retrieved on: 
Thursday, May 20, 2021
Medical specialties, Clinical medicine, Medicine, Digestive system, Dysbiosis, Probiotic, Lymphoma, Diarrhea, Placebo

al) suggests that Visbiome Vet probiotic may help mitigate occasional gastrointestinal concerns in dogs undergoing chemotherapy treatment for lymphoma.\nThe study was conducted at Kansas State University.

Key Points: 
  • al) suggests that Visbiome Vet probiotic may help mitigate occasional gastrointestinal concerns in dogs undergoing chemotherapy treatment for lymphoma.\nThe study was conducted at Kansas State University.
  • Ten dogs with multicentric lymphoma were enrolled in this prospective, randomized, placebo-controlled, single-blinded study.
  • Dogs either received an oral probiotic or an oral placebo daily.\nForty percent of dogs had an unbalanced GI microbiome at baseline, and dysbiosis was common in dogs with multicentric lymphoma.\nResults were promising.
  • Not one dog receiving probiotics experienced occasional diarrhea, compared to 4 out of 5 dogs who received the placebo.

KÖE Combines the Power of Probiotics with Trending Watermelon and Tropical Flavors

Retrieved on: 
Thursday, May 20, 2021
Bacteriology, Digestive system, Probiotic, Flavor, Branches of biology

Carefully crafted with billions of probiotics, KE Tropical and KE Watermelon will be available in 12 oz.

Key Points: 
  • Carefully crafted with billions of probiotics, KE Tropical and KE Watermelon will be available in 12 oz.
  • Life Magazine calls watermelon one of the most memorable flavors in American life, and according to Fona International, watermelon sees 24 mentions per minute on social media.
  • "\nAll of KE\'s authentically fermented, lightly sparkling flavors are packed with billions of live, high-grade bacillus coagulan probiotics.
  • All seven KE flavors are vegan, gluten-free, certified Kosher and made with black tea, natural fruit flavors and purees, and a touch of 100% organic cane sugar.

Emulate Announces Colon Intestine-Chip Grant Program to Inspire Research into Intestinal Diseases

Retrieved on: 
Tuesday, May 18, 2021
Medical specialties, Organ systems, Clinical medicine, Digestive system, Inflammatory bowel disease, Irritable bowel syndrome, Gastrointestinal tract, Large intestine, Intestinal mucosal barrier, Dietary fiber

b'BOSTON, May 18, 2021 /PRNewswire/ --Emulate, Inc., a leading provider of advanced in vitro models, today launched theEmulate Colon Intestine-Chip Grant Program.

Key Points: 
  • b'BOSTON, May 18, 2021 /PRNewswire/ --Emulate, Inc., a leading provider of advanced in vitro models, today launched theEmulate Colon Intestine-Chip Grant Program.
  • The program will help researchers begin using Organs-on-Chips technology to study intestinal diseases.
  • The Emulate Colon Intestine-Chip is a physiologically-relevant model of the human colon which can be used to study and test potential treatments for inflammatory bowel disease, irritable bowel syndrome, leaky gut, celiac disease, and more.\nThe Emulate Colon Intestine-Chip allows researchers to recapitulate specific human colon cell functionality, gain a greater understanding of mechanisms of intestinal disease, and investigate potential drug targets.
  • "We know that the intestinal barrier is critical to human health and that inflammation has been implicated in many diseases.

ZOE Launches #bluepoopchallenge to Help People Learn About Their Gut Health

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Digestive system, Microbiomes, Environmental microbiology, Bacteriology, Firmicutes, Gut microbiota, Microbiome, Gastrointestinal tract

To explore the links between transit time, gut microbes, and health, ZOE analyzed the gut microbiomes of each blue pooper and collected significant data about their diet and health.\nDr.

Key Points: 
  • To explore the links between transit time, gut microbes, and health, ZOE analyzed the gut microbiomes of each blue pooper and collected significant data about their diet and health.\nDr.
  • Our data shows that transit time, tracked with blue dye, is an indicator of gut health, and is better than other non-invasive methods available.
  • Spector continued, "The Blue Poop Challenge is a simple way to find out what is going on in your gut.
  • The Blue Poop Challenge is a fun and engaging program designed to drive awareness of how important your gut health is.

HempFusion Wellness Inc. Announces 2021 AGM Voting Results

Retrieved on: 
Monday, May 17, 2021
Alternative medicine, Retail, Health, Tobacco, Agriculture, Natural Resources, Bacteriology, Digestive system, Probiotic, Hemp, System for Electronic Document Analysis and Retrieval, Articles

Detailed voting results are available under the Company\xe2\x80\x99s profile on SEDAR at www.sedar.com .\nHempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.

Key Points: 
  • Detailed voting results are available under the Company\xe2\x80\x99s profile on SEDAR at www.sedar.com .\nHempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition.
  • HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations.
  • With a strong focus on research and development, HempFusion has an additional 30 products under development.
  • HempFusion is a board member of the US Hemp Roundtable, and HempFusion\xe2\x80\x99s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data.

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021

Retrieved on: 
Monday, May 17, 2021
Medical specialties, Branches of biology, Clinical medicine, Bacteriology, Microbiomes, Diarrhea, Environmental microbiology, Digestive system, Clostridioides difficile, Gut microbiota, Human microbiome, Gastrointestinal tract

\xe2\x80\x93 a germ (bacterium) that can cause severe diarrhea and colitis (an inflammation of the colon).

Key Points: 
  • \xe2\x80\x93 a germ (bacterium) that can cause severe diarrhea and colitis (an inflammation of the colon).
  • C. difficile can live naturally in the intestines (gut) of humans and not cause any problem.
  • Sometimes changes in the gut microbiome lead the bacteria to grow and produce toxins from which illness can develop.iv\nC.
  • Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids.